ABIONYX Pharma Completes Successful EUR 33 Million Financing

ABIONYX Pharma announced a successful capital increase of EUR 18.7 million through issuing 7,056,416 new shares at EUR 2.65 each. Existing shareholders subscribed to approximately 40% of the capital increase with the exercise of subscription rights and guarantee commitments. The company also secured EUR 10 million from Fenja Capital in the first tranche of a planned EUR 14 million bond financing. This funding extends ABIONYX's cash runway to Q4 2028.

The raised capital and bonds will fund a Phase 2b clinical trial in sepsis and a Marketing Authorization Application for LCAT deficiency, securing financial support and operational growth. The company expects the settlement and delivery of new shares on June 22, 2026.

ABIONYX's CEO, Cyrille Tupin, highlighted the enhanced financial stability and shareholder support as strategic advantages in advancing drug candidates like CER-001 in sepsis.